Cyclopharm Ltd, a prominent player in the health care sector, has been making significant strides in the field of radiopharmaceuticals. Based in Melbourne, Australia, the company specializes in providing radiopharmaceutical products specifically designed for lung and cancer tumor imaging. These products are crucial for the medical profession, aiding in the diagnosis and treatment of various conditions.

As of October 9, 2025, Cyclopharm Ltd’s share price closed at 0.67 AUD, marking the 52-week low for the company. This figure contrasts with the 52-week high of 2.5 AUD, recorded on January 22, 2025. The fluctuation in share price reflects the dynamic nature of the health care equipment and supplies industry, influenced by various market factors and company performance metrics.

Cyclopharm Ltd is listed on the ASX All Markets, a primary exchange that provides a platform for the company to engage with investors and stakeholders. The company’s market capitalization stands at 74,461,722 AUD, indicating its valuation in the market and its financial standing relative to its peers.

The company’s journey began with its Initial Public Offering (IPO) on January 19, 2007. Since then, Cyclopharm Ltd has established itself as a key supplier of radiopharmaceuticals, focusing on innovation and quality to meet the needs of the medical community. The company’s offerings are detailed on its website, www.cyclopharm.com.au , where potential clients and investors can find comprehensive information about its products and services.

Cyclopharm Ltd’s commitment to serving the medical profession is evident in its specialized product range, which plays a vital role in enhancing diagnostic capabilities for lung and cancer-related conditions. As the company continues to navigate the challenges and opportunities within the health care sector, its focus remains on delivering high-quality radiopharmaceutical solutions to support medical advancements.